On March 30, 2007 the U.S. Food and Drug Administration (FDA) announced that Novartis Pharmaceuticals had agreed to the FDA’ request that they voluntarily discontinue marketing and sales of Zelnorm (tegaserod maleate). Continue reading ⇒
Filed under:
